Weight-Related Effects on Disease Progression in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial

Gastroenterology

Volumn 137, Issue 2, 2009, Pages 549-557

  Everhart, James E ^a   Lok, Anna S ^b   Kim, Hae Young ^c   Morgan, Timothy R ^d,e   Lindsay, Karen L ^f   Chung, Raymond T ^g   Bonkovsky, Herbert L ^h   Ghany, Marc G ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NEW ENGLAND RESEARCH INSTITUTES   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; DIABETES MELLITUS; DISEASE COURSE; FATTY LIVER; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

EID: 67651095837     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.05.007     Document Type: Article

References (24)

1. Lee W.M., Dienstag J.L., Lindsay K.L., et al. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials 25 (2004) 472-492
2. Di Bisceglie A.M., Shiffman M.L., Everson G.T., et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359 (2008) 2429-2441
3. Ainsworth B.E., Haskell W.L., Whitt M.C., et al. Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 32 suppl (2000) S498-S504
4. Crespo C.J., Keteyian S.J., Heath G.W., and Sempos C.T. Leisure-time physical activity among US adults. Results from the Third National Health and Nutrition Examination Survey. Arch Intern Med 156 (1996) 93-98
5. Hayashi M., Floyd Jr. J.C., Pek S., and Fajans S.S. Insulin, proinsulin, glucagon and gastrin in pancreatic tumors and in plasma of patients with organic hyperinsulinism. J Clin Endocrinol Metab 44 (1977) 681-694
6. Wallace T.M., Levy J.C., and Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 27 (2004) 1487-1495
7. Ishak K., Baptista A., Bianchi L., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995) 696-699
8. Leandro G., Mangia A., Hui J., et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130 (2006) 1636-1642
9. Petta S., Camma C., Marco V.D., et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 103 (2008) 1136-1144
10. Hu K.Q., Kyulo N.L., Esrailian E., et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol 40 (2004) 147-154
11. Friedenberg F., Pungpapong S., Zaeri N., and Braitman L.E. The impact of diabetes and obesity on liver histology in patients with hepatitis C. Diabetes Obes Metab 5 (2003) 150-155
12. Younossi Z.M., McCullough A.J., Ong J.P., et al. Obesity and nonalcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 38 (2004) 705-709
13. Cholet F., Nousbaum J.B., Richecoeur M., et al. Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. Gastroenterol Clin Biol 28 (2004) 272-278
14. Wyatt J., Baker H., Prasad P., Gong Y.Y., and Millson C. Steatosis and fibrosis in patients with chronic hepatitis C. J Clin Pathol 57 (2004) 402-406
15. Lok A.S., Everhart J.E., Chung R.T., et al. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol 5 (2007) 245-254
16. Asselah T., Boyer N., Guimont M.C., et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 52 (2003) 1638-1643
17. Perumalswami P., Kleiner D.E., Lutchman G., et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology 43 (2006) 780-787
18. Castera L., Hezode C., Roudot-Thoraval F., et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 52 (2003) 288-292
19. Lok A.S., Everhart J.E., Chung R.T., et al. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis trial (HALT-C) trial. Hepatology 49 (2009) 1828-1837
20. Ruhl C.E., and Everhart J.E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 124 (2003) 71-79
21. Cowie C.C., Rust K.F., Byrd-Holt D.D., et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 29 (2006) 1263-1268
22. Hickman I.J., and Macdonald G.A. Impact of diabetes on the severity of liver disease. Am J Med 120 (2007) 829-834
23. Kotronen A., Vehkavaara S., Seppala-Lindroos A., Bergholm R., and Yki-Jarvinen H. Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab 293 (2007) E1709-E1715
24. Farrell G.C., and Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 43 suppl (2006) S99-S112